Pfizer Stock Screener | Share Price & Fundamental Analysis
PFIZER
Pharmaceuticals
Share Price NSE
₹4887.10
▲
34.10 (0.70%)
Share Price BSE
₹4881.95
▲
30.05 (0.62%)
Track Pfizer share price live with TickJournal's free stock screener.
Analyze Pfizer share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Pfizer Market Cap
₹21,544.89 Cr.
PFIZER P/E Ratio (TTM)
25.00
Pfizer P/B Ratio
5.55
EPS (TTM)
₹136.46
Dividend Yield
3.54%
Debt to Equity
0.01
PFIZER 52 Week High
₹5889.00
Pfizer 52 Week Low
₹3913.75
Operating Margin
34.00%
Profit Margin
30.00%
PFIZER Revenue (TTM)
₹2,847.00
EBITDA
₹1,202.00
Net Income
₹854.00
Total Assets
₹4,911.00
Total Equity
₹4,217.00
Pfizer Share Price History - Stock Screener Chart
Screen PFIZER historical share price movements with interactive charts. Analyze price trends and patterns.
Pfizer Company Profile - Fundamental Screener
Screen Pfizer company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for PFIZER shares.
Pfizer Limited is an Indian pharmaceutical company engaged in manufacturing, marketing, trading, and exporting pharmaceutical products. It has a manufacturing facility in Goa and works with contract manufacturers across India. The company offers a diverse portfolio of products including vaccines, anti-infectives, cardiac medications, pain relief, maternal nutrition, gastrointestinal treatments, contraceptives,...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Pradip P Shah
ISIN
INE182A01018
Website
https://www.pfizerindia.com
Pfizer Balance Sheet Screener
Screen PFIZER balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 4,911 | 4,229 | 4,001 | 3,901 | 3,266 | 4,405 | 3,940 | 3,690 | 3,261 | 2,914 |
| Current Assets | 3,513 | 2,738 | 2,525 | 2,397 | 1,925 | 3,048 | 2,715 | 2,417 | 2,051 | 1,630 |
| Fixed Assets | 724 | 713 | 749 | 869 | 894 | 973 | 886 | 950 | 902 | 895 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 124 | 87 | 136 | 183 | 99 | 137 | 37 | 52 | 62 | 36 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 4,217 | 3,596 | 3,207 | 2,864 | 2,393 | 3,396 | 3,011 | 2,683 | 2,419 | 2,118 |
| Share Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves & Surplus | 4,172 | 3,550 | 3,162 | 2,819 | 2,347 | 3,350 | 2,966 | 2,637 | 2,373 | 2,072 |
Pfizer Income Statement Screener - Profit & Revenue Analysis
Screen Pfizer income statement and profit fundamentals.
Analyze PFIZER quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Pfizer share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,847 | 2,454 | 2,374 | 2,526 | 2,674 | 2,320 | 2,336 | 2,249 | 2,083 | 2,067 | 2,103 | 1,921 |
| Expenses | 1,645 | 1,541 | 1,558 | 1,616 | 1,775 | 1,526 | 1,579 | 1,516 | 1,468 | 1,617 | 1,586 | 1,470 |
| EBITDA | 1,202 | 913 | 816 | 910 | 898 | 793 | 757 | 733 | 615 | 450 | 517 | 450 |
| Operating Profit % | 34.00% | 32.00% | 29.00% | 33.00% | 32.00% | 32.00% | 27.00% | 27.00% | 25.00% | 18.00% | 21.00% | 21.00% |
| Depreciation | 59 | 61 | 62 | 106 | 115 | 109 | 103 | 71 | 66 | 63 | 124 | 131 |
| Interest | 10 | 8 | 15 | 13 | 11 | 15 | 11 | 1 | 0 | 1 | 1 | 1 |
| Profit Before Tax | 1,133 | 1,016 | 746 | 824 | 773 | 669 | 643 | 660 | 548 | 517 | 402 | 238 |
| Tax | 290 | 249 | 195 | 200 | 160 | 171 | 133 | 231 | 188 | 180 | 179 | 138 |
| Net Profit | 854 | 768 | 551 | 624 | 613 | 498 | 509 | 429 | 360 | 337 | 223 | 100 |
| EPS | 186.60 | 136.46 | 119.22 | 136.38 | 133.89 | 108.77 | 111.28 | 93.78 | 78.70 | 73.61 | 66.66 | 15.26 |
Pfizer Cash Flow Screener - Liquidity Fundamentals
Screen PFIZER cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 660 | 257 | 356 | 667 | 427 | 323 | 98 | 332 | 329 | 346 |
| Investing Activities | -71 | 54 | -36 | -575 | -469 | 1,530 | 35 | -238 | -250 | -701 |
| Financing Activities | -205 | -235 | -346 | -181 | -1,571 | -164 | -110 | -110 | -83 | -62 |
| Net Cash Flow | 383 | 75 | -26 | -88 | -1,613 | 1,690 | 23 | -17 | -4 | -417 |
Pfizer Shareholding Pattern Screener
See Pfizer shareholding pattern with promoter, FII, and DII holdings.
Check Pfizer promoter holding and ownership changes for PFIZER on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% |
| FII Holding | 2.18% | 2.39% | 2.60% | 2.71% | 3.33% | 3.22% | 3.54% | 2.75% |
| DII Holding | 17.10% | 17.23% | 17.10% | 17.05% | 15.33% | 15.84% | 16.03% | 16.79% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 12.34% | 12.02% | 12.08% | 11.93% | 12.90% | 12.55% | 12.15% | 12.12% |
| Other Holding | 4.45% | 4.43% | 4.29% | 4.39% | 4.52% | 4.46% | 4.35% | 4.41% |
| Shareholder Count | 108,261 | 103,222 | 103,480 | 100,933 | 109,214 | 106,098 | 98,824 | 105,015 |
Pfizer Share Dividend Screener - Share Yield Analysis
Check Pfizer dividend history with payout and yield data.
View Pfizer dividend details including ex-dates and amounts for PFIZER stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹165.00 | 3.54% |
| 2024-March | ₹35.00 | 0.87% |
| 2023-March | ₹40.00 | 0.95% |
| 2022-March | ₹35.00 | 1.00% |
| 2021-March | ₹35.00 | 0.80% |
| 2020-March | ₹330.00 | 7.29% |
| 2019-March | ₹22.50 | 0.56% |
| 2018-March | ₹20.00 | 0.60% |
| 2017-March | ₹20.00 | 0.92% |
Pfizer Stock Index Membership
See which indices include Pfizer stock.
Check PFIZER index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY SMALLCAP250 QUALITY 50
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 MULTICAP
Pfizer Market Events Screener - Corporate Actions
Get Pfizer corporate actions including splits, bonuses, and buybacks.
Check Pfizer stock events that may affect PFIZER share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2022-02-20 | Dividend | ₹ 30.00 /share | 1.61% | |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | -0.19% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -4.06% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 0.68% |
| 2025-07-21 | 2025-07-21 | Annual General Meeting | NA | 20.59% |
| 2025-07-09 | 2025-07-09 | Dividend | ₹ 30.00 /share | 32.64% |
| 2025-07-09 | 2025-07-09 | Dividend | ₹ 35.00 /share | 32.64% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 3.80% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -5.60% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -6.42% |
| 2024-08-28 | 2024-08-28 | Annual General Meeting | NA | 0.34% |
| 2024-08-21 | 2024-08-21 | Dividend | ₹ 35.00 /share | 36.12% |
| 2023-08-11 | 2023-08-11 | Dividend | ₹ 35.00 /share | 7.07% |
| 2023-08-11 | 2023-08-11 | Dividend | ₹ 5.00 /share | 7.07% |
| 2022-08-18 | 2022-08-19 | Dividend | ₹ 35.00 /share | -1.09% |
Pfizer Competitors Screener - Peer Comparison
Screen PFIZER competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 430,777 | 38.40 | 54,729 | 9.71% | 10,980 | 56.77 |
| Divis Laboratories | 159,666 | 64.50 | 9,712 | 18.67% | 2,191 | 40.37 |
| Torrent Pharmaceuticals | 145,447 | 63.41 | 11,539 | 6.99% | 1,911 | 52.50 |
| Dr Reddys Laboratories | 108,560 | 19.04 | 33,741 | 16.73% | 5,725 | 53.74 |
| Lupin | 107,238 | 22.82 | 22,910 | 13.74% | 3,306 | 59.20 |
| Cipla | 100,519 | 21.73 | 28,410 | 7.12% | 5,291 | 35.20 |
| Zydus Life Science | 90,933 | 17.75 | 23,511 | 18.55% | 4,615 | 51.17 |
| Mankind Pharma | 83,552 | 45.50 | 12,744 | 20.90% | 2,007 | 43.19 |
| Aurobindo Pharma | 75,957 | 21.35 | 32,346 | 9.43% | 3,484 | 62.57 |
| Alkem Laboratories | 64,990 | 26.15 | 13,458 | 3.70% | 2,216 | 49.75 |
Pfizer Company Announcements - News Screener
Screen PFIZER latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-09 | Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025. | - |
| 2026-02-05 | Newspaper Advertisement | - |
| 2026-01-30 | Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025. | - |
| 2026-01-20 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-01-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-29 | Closure of Trading Window | - |
| 2025-12-28 | Disclosure under Regulation 30A of LODR | - |
| 2025-12-24 | Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2025-12-23 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-12-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2025-12-19 | Exclusive Supply And Marketing Agreement With Cipla Limited For Certain Products. | - |
| 2025-11-12 | Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | - |
| 2025-11-03 | Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025. | - |
| 2025-10-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-09-29 | Closure of Trading Window | - |
| 2025-08-13 | Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025 | - |
| 2025-08-13 | Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025 | - |
| 2025-08-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2025-08-11 | Launch Of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P. 20 - Valent (PCV20) | - |
| 2025-08-07 | Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30 2025 | - |